The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA

Yumei Ye, Kyle T. Keyes, Congfang Zhang, Jose R. Perez-Polo, Yu Lin, Yochai Birnbaum

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Pioglitazone (PIO) and glucagon-like peptide-1 (GLP-1) analogs limit infarct size (IS) in experimental models. The effects of the dipeptidylpeptidase-IV inhibitors, which increase the endogenous levels of GLP-1, on myocardial protection, are unknown. We studied whether sitagliptin (SIT) and PIO have additive effects on IS limitation in the mouse. Mice received 3-day or 14-day oral SIT (300 mg·kg-1·day -1), PIO (5 mg·kg-1·day-1), SIT + PIO, or vehicle. In addition, mice received intravenous H-89 [20 mg/kg, a protein kinase A (PKA) inhibitor] or vehicle 1 h before ischemia. Rats underwent 30 min myocardial ischemia and 4 h reperfusion. SIT, PIO, and SIT + PIO for 3 days significantly reduced IS (24.3 ± 2.7, 23.0 ± 0.8, and 14.7 ± 0.9%) compared with controls (46.2 ± 2.8%). H-89 completely blocked the effect of SIT and partially blocked the PIO effect. SIT, but not PIO, increased cAMP levels. PKA activity was increased by PIO and to a greater extent by SIT. PIO, but not SIT, increased cytosolic phospholipase A2 and cyclooxygenase-2 activity. Accordingly, 6-keto-PGF and 15-deoxy-PGJ2 increased by PIO but not SIT. In contrast, SIT, and to a lesser extent PIO, increased 15-epi-lipoxin A4 levels. H-89 completely blocked the effect of SIT and PIO on 15-epi-lipoxin A4 levels. PIO, and to a greater extent SIT, increased endothelial nitric oxide synthase and cAMP response element-binding protein phosphorylation, an effect that was blocked by H-89. With a 14-day pretreatment experiment, IS was 46.4 ± 1.0% in the control group, 16.9 ± 0.6% in SIT (P < 0.001), 19.1 ± 1.1% in PIO (P = 0.014), and 12.9 ± 0.7% in SIT + PIO (P < 0.001). We found that SIT and PIO limit IS using different pathways. The protective effect of SIT is via cAMP-dependent PKA activation, whereas PIO mediates its effects via both PKA-dependent and -independent pathways.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume298
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

pioglitazone
Cyclic AMP-Dependent Protein Kinases
Myocardial Infarction
Sitagliptin Phosphate
Glucagon-Like Peptide 1

Keywords

  • Adenosine 3′-5′-cyclic monophosphate
  • Protein kinase A

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. / Ye, Yumei; Keyes, Kyle T.; Zhang, Congfang; Perez-Polo, Jose R.; Lin, Yu; Birnbaum, Yochai.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 298, No. 5, 05.2010.

Research output: Contribution to journalArticle

@article{fd2e6ea18a6f4457ae19f2bd8051d6fb,
title = "The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA",
abstract = "Pioglitazone (PIO) and glucagon-like peptide-1 (GLP-1) analogs limit infarct size (IS) in experimental models. The effects of the dipeptidylpeptidase-IV inhibitors, which increase the endogenous levels of GLP-1, on myocardial protection, are unknown. We studied whether sitagliptin (SIT) and PIO have additive effects on IS limitation in the mouse. Mice received 3-day or 14-day oral SIT (300 mg·kg-1·day -1), PIO (5 mg·kg-1·day-1), SIT + PIO, or vehicle. In addition, mice received intravenous H-89 [20 mg/kg, a protein kinase A (PKA) inhibitor] or vehicle 1 h before ischemia. Rats underwent 30 min myocardial ischemia and 4 h reperfusion. SIT, PIO, and SIT + PIO for 3 days significantly reduced IS (24.3 ± 2.7, 23.0 ± 0.8, and 14.7 ± 0.9{\%}) compared with controls (46.2 ± 2.8{\%}). H-89 completely blocked the effect of SIT and partially blocked the PIO effect. SIT, but not PIO, increased cAMP levels. PKA activity was increased by PIO and to a greater extent by SIT. PIO, but not SIT, increased cytosolic phospholipase A2 and cyclooxygenase-2 activity. Accordingly, 6-keto-PGF1α and 15-deoxy-PGJ2 increased by PIO but not SIT. In contrast, SIT, and to a lesser extent PIO, increased 15-epi-lipoxin A4 levels. H-89 completely blocked the effect of SIT and PIO on 15-epi-lipoxin A4 levels. PIO, and to a greater extent SIT, increased endothelial nitric oxide synthase and cAMP response element-binding protein phosphorylation, an effect that was blocked by H-89. With a 14-day pretreatment experiment, IS was 46.4 ± 1.0{\%} in the control group, 16.9 ± 0.6{\%} in SIT (P < 0.001), 19.1 ± 1.1{\%} in PIO (P = 0.014), and 12.9 ± 0.7{\%} in SIT + PIO (P < 0.001). We found that SIT and PIO limit IS using different pathways. The protective effect of SIT is via cAMP-dependent PKA activation, whereas PIO mediates its effects via both PKA-dependent and -independent pathways.",
keywords = "Adenosine 3′-5′-cyclic monophosphate, Protein kinase A",
author = "Yumei Ye and Keyes, {Kyle T.} and Congfang Zhang and Perez-Polo, {Jose R.} and Yu Lin and Yochai Birnbaum",
year = "2010",
month = "5",
doi = "10.1152/ajpheart.00867.2009",
language = "English (US)",
volume = "298",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA

AU - Ye, Yumei

AU - Keyes, Kyle T.

AU - Zhang, Congfang

AU - Perez-Polo, Jose R.

AU - Lin, Yu

AU - Birnbaum, Yochai

PY - 2010/5

Y1 - 2010/5

N2 - Pioglitazone (PIO) and glucagon-like peptide-1 (GLP-1) analogs limit infarct size (IS) in experimental models. The effects of the dipeptidylpeptidase-IV inhibitors, which increase the endogenous levels of GLP-1, on myocardial protection, are unknown. We studied whether sitagliptin (SIT) and PIO have additive effects on IS limitation in the mouse. Mice received 3-day or 14-day oral SIT (300 mg·kg-1·day -1), PIO (5 mg·kg-1·day-1), SIT + PIO, or vehicle. In addition, mice received intravenous H-89 [20 mg/kg, a protein kinase A (PKA) inhibitor] or vehicle 1 h before ischemia. Rats underwent 30 min myocardial ischemia and 4 h reperfusion. SIT, PIO, and SIT + PIO for 3 days significantly reduced IS (24.3 ± 2.7, 23.0 ± 0.8, and 14.7 ± 0.9%) compared with controls (46.2 ± 2.8%). H-89 completely blocked the effect of SIT and partially blocked the PIO effect. SIT, but not PIO, increased cAMP levels. PKA activity was increased by PIO and to a greater extent by SIT. PIO, but not SIT, increased cytosolic phospholipase A2 and cyclooxygenase-2 activity. Accordingly, 6-keto-PGF1α and 15-deoxy-PGJ2 increased by PIO but not SIT. In contrast, SIT, and to a lesser extent PIO, increased 15-epi-lipoxin A4 levels. H-89 completely blocked the effect of SIT and PIO on 15-epi-lipoxin A4 levels. PIO, and to a greater extent SIT, increased endothelial nitric oxide synthase and cAMP response element-binding protein phosphorylation, an effect that was blocked by H-89. With a 14-day pretreatment experiment, IS was 46.4 ± 1.0% in the control group, 16.9 ± 0.6% in SIT (P < 0.001), 19.1 ± 1.1% in PIO (P = 0.014), and 12.9 ± 0.7% in SIT + PIO (P < 0.001). We found that SIT and PIO limit IS using different pathways. The protective effect of SIT is via cAMP-dependent PKA activation, whereas PIO mediates its effects via both PKA-dependent and -independent pathways.

AB - Pioglitazone (PIO) and glucagon-like peptide-1 (GLP-1) analogs limit infarct size (IS) in experimental models. The effects of the dipeptidylpeptidase-IV inhibitors, which increase the endogenous levels of GLP-1, on myocardial protection, are unknown. We studied whether sitagliptin (SIT) and PIO have additive effects on IS limitation in the mouse. Mice received 3-day or 14-day oral SIT (300 mg·kg-1·day -1), PIO (5 mg·kg-1·day-1), SIT + PIO, or vehicle. In addition, mice received intravenous H-89 [20 mg/kg, a protein kinase A (PKA) inhibitor] or vehicle 1 h before ischemia. Rats underwent 30 min myocardial ischemia and 4 h reperfusion. SIT, PIO, and SIT + PIO for 3 days significantly reduced IS (24.3 ± 2.7, 23.0 ± 0.8, and 14.7 ± 0.9%) compared with controls (46.2 ± 2.8%). H-89 completely blocked the effect of SIT and partially blocked the PIO effect. SIT, but not PIO, increased cAMP levels. PKA activity was increased by PIO and to a greater extent by SIT. PIO, but not SIT, increased cytosolic phospholipase A2 and cyclooxygenase-2 activity. Accordingly, 6-keto-PGF1α and 15-deoxy-PGJ2 increased by PIO but not SIT. In contrast, SIT, and to a lesser extent PIO, increased 15-epi-lipoxin A4 levels. H-89 completely blocked the effect of SIT and PIO on 15-epi-lipoxin A4 levels. PIO, and to a greater extent SIT, increased endothelial nitric oxide synthase and cAMP response element-binding protein phosphorylation, an effect that was blocked by H-89. With a 14-day pretreatment experiment, IS was 46.4 ± 1.0% in the control group, 16.9 ± 0.6% in SIT (P < 0.001), 19.1 ± 1.1% in PIO (P = 0.014), and 12.9 ± 0.7% in SIT + PIO (P < 0.001). We found that SIT and PIO limit IS using different pathways. The protective effect of SIT is via cAMP-dependent PKA activation, whereas PIO mediates its effects via both PKA-dependent and -independent pathways.

KW - Adenosine 3′-5′-cyclic monophosphate

KW - Protein kinase A

UR - http://www.scopus.com/inward/record.url?scp=77951812608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951812608&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00867.2009

DO - 10.1152/ajpheart.00867.2009

M3 - Article

VL - 298

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 5

ER -